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Introduction:  
      Acinetobaceracter species mainly Acinetobacter baumannii has emerged as 
an important and problematic human pathogen as it is the causative agent of 
several types of infections including pneumonia, meningitis, septicemia, and 
urinary tract infections. Acinetobacter species isolates are frequently resistant to 
multiple antibiotic classes through an array of resistant mechanism leading to 
multi and pan drug resistance. Characterization of antibiotic resistance genes in A. 
baumannii, is necessary to control further dissemination of these antibiotic 
resistant genes. Treatment of multidrug-resistant bacterial infections poses a 
therapeutic challenges, combination therapy is often the only viable option for 
multidrug-resistant and pandrug-resistant infections. 
 
Aim:  
Detection of genotypes of Carbapenamase present in multi and pan drug 
resistant Acinetobacter baumanii isolated from the clinical samples, and identify 
the best combination of drugs for effective and management of multidrug-resistant 
isolates.  
1.  Material and Methods:  
             Acinetobacter species were characterized by conventional phenotypic 
methods and vitek automated microbial identification system. Phenotypic and 
genotypic methods were used to characterize the mechanisms of resistance in 
Acinetobacter baumannii.i Checker board method was used to perform drug 
synergy test using Rifampin Amikacin Sulbactam Ciprofloxacin and Imipenem in 
combination with Colistin. 
 
Result: 
 Acinetobacter baumannii  was the most common species isolated in the 
hospital of which 73% were multidrug resistant and 50.02% were carbapenem 
resistant, MBL () AmpC() The molecular study showed OXA 51 was seen 100% 
and OXA 23 was in 93.05% . Better synergy was observed with rifampin (80%) 
and imipenem (77.77%) with colistin and poor synergy was seen with 
ciprofloxacin and colistin combination (10%).  
Conclusion:  
Acinetobacter baumannii is one of the important nococomial pathogen 
which showed high incidence of carbapenem resistance (58.03%) best synergy was 
observed with colistin and rifampin (80%) followed by imipenem (77.77%) most 
common OXA gene found in our study were OXA 51 and OXA 23.   
 
  
INTRODUCTION 
                         Acinetobacter species are non motile, oxidase negative 
coccobacilli, which is currently classified to Moraxellaceae1. It consists of 
at least 12 DNA hybridization groups referred to as genospecies. 
Genospecies 1 is the type species A.calcoacticus and was isolated from the 
soil. Genospecies 2 is Acinetobacter baumannii and is the most prevalent 
species in human clinical isolates2-3.  
 
             Acinetobacter is a gram negative cocco-bacillary cell which 
often appears as diplcocci. After 24 hours of growth on blood agar, the 
colonies are between 0.5 and 2 mm in diameter translucent and opaque 
convex and entire. Most strains grow well in Mac-conkey agar which are 
pale lactose fermenting colonies. Presumptive identification of 
Acinetobacter species is made on the basis of the lack of cytochrome 
oxidase activity, lack of motility and resistance to penicillin. A baumannii is 
a saccharolytic and acidifies most OF carbohydrates; identification is made 
by demonstration of the rapid acid production of acid from lactose 1 & 10 % 
concentrations. 
 
                     There has been extensive research done on the virulence factor 
of Acinetobacter but only little is known about the true pathogenic potential. 
The factors which contribute to its virulence include outer membrane 
proteins (OMPs)11, biofilm formation that allows the bacteria to grow in 
unfavorable conditions  with the help of the protein called BAP(biofilm-
associated protein).12 The other virulence factor include phospholipase D 
and C, that causes resistance in human serum and invasion of epithelial cell, 
while phospholipase C causes toxicity in epithelial cells13   
 
                      A.baumannii is the species most prevalent in clinical 
specimens and most often responsible for hospital acquired infections. Other 
species such as A.johnsonnii, A lwoffii seem to be natural inhabitance of the 
human skin and may also be commensals in the oropharynx and vagina3.A 
variety of human infections have been viewed by Lyons et al, including 
pneumonia, endocarditis, meningitis, skin and wound infections, peritonitis 
and urinary tract infection sporadic cases of conjunctivitis, osteomyelitis, 
and synovitis have also been reported5. They have been implicated in a 
various nosocomial infections, including bacteremia, urinary tract infection, 
secondary meningitis but their predominant role in ventilator-associated 
pneumonia confined to hospital intensive-care units.6 
                             Acinetobacter species tends to be resistant to a variety of 
antibiotics, although one species, A lwoffii tends to be more sensitive than 
the others. There is almost universal resistance to penicillin, ampicillin and 
cephlothin and most strains are resistant to chloramphenicol7. It has been 
noticed that there is an increased trend for aminoglycosides resistance 
among the Acinetobacter species. In recent years multiple drug resistant 
strains, including carbapenems-resistant Acinetobacter species have been 
reported in nosocomial outbreaks.8 
 
                            The resistance mechanisms for the various drug resistances 
in Acinetobacter are not studied extensively but found be similar to 
Pseudomonas spp18. The drug resistance mechanisms are based on the 
principle of  
• Antimicrobial-inactivating enzymes, wide range of beta-lactamases 
that hydrolyze penicillins, cephalosporins and carbapenems19. 
• reduced access to bacterial targets,  
• mutations that change targets or cellular functions20 
 
 
                               Combination treatment with an aminoglycoside and 
ticarcillin or piperacillin is synergistic and may be effective in serious 
infections. For multiply resistant Acinetobacter infection several studies 
have demonstrated clinical efficiency of sulbactam in combination with 
ampicillin or cefoperazone. The other antimicrobial agent that has shown to 
be active against multiply resistant Acinetobacter is colistin9-10. 
 
                             Various studies have shown an in vitro evidence of 
heteroresistance among the colistin susceptible Acinetobacter isolates. The 
proportion of colistin resistant subpopulation is significantly increased by 
serial passages of the isolates in the presence of colistin. Combination 
therapy is advisable over monotherapy with colistin in order to prevent the 
emergence of heteroresistance21.  
 
                          Ventilator associated pneumonia is often associated with 
Acinetobacter due to the factors such as long period of hospitalization 
longer period on ventilators and use of broad spectrum of antibiotics which 
are considered to be some of the risk factors. In Intensive care unit the 
mortality rate was higher ranging between 26%-68% 14 and further increase 
in mortality rate in colonization15.  In blood stream infections the mortality 
 was between 34%-43.4% in the intensive care unit and 16.3% outside the 
intensive care unit, Acinetobacter blood stream infections is the third 
highest cause of mortality followed only by P.aeruginosa and candida spp 
infections16, but the alternate reason for the marked increase in mortality 
could be the patients’ severe underlying illness and not an independent risk 
factor for mortality.17   
 
                                In this study, we would like to speciate Acinetobacter 
isolates and study the effect of combination of drugs on multidrug resistant 
and pan drug resistant Acinetobacter which will help in the management of 
the patient with these infections. 
 
                               We would also like to characterize the mechanism of 
resistance by studying OXA sub types.   
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       2.  AIM AND OBJECTIVES  
 AIM OF THE STUDY 
 
Primary Objectives 
 
Detection of genotypes of Carbapenamase present in multi and pan drug 
resistant Acinetobacter baumanii isolated from the clinical samples. 
 
Secondary Objectives:  
 
1. Isolation and characterization of Acinetobacter by conventional 
phenotypic methods and vitek automated microbial identification 
system. 
 
2. Phenotypic detection of drug resistance mechanism by Modified 
Hodge Test and Combined EDTA disk test. 
 
 
3. Drug synergy testing by checker board method using Rifampin 
Amikacin Sulbactam Ciprofloxacin and Imipenem in combination 
with Colistin. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
4.                 REVIEW OF LITERATURE 
 
 
 REVIEW OF LITERATURE 
 
HISTORICAL PERSPECTIVE OFACINETOBACTER: 
                                   Acinetobacter was first isolated by a Dutch 
microbiologist, Beijerinck from the soil using minimal media enriched with 
calcium acetate in the year 1911.22 The name Acinetobacter was proposed 
later by Brisou and Prevot which was originally described as Micrococcus 
calco-aceticus, over 40 years ago when it was differentiated from the motile 
genus Acromobacter. It was accepted as a genus which could not be 
differentiated in to further species based on the phenotypical characters 
when an extensive study on the organism was done. In the committee on the 
Taxonomy of Morraxella and Allied Bacteria sub-committee officially 
accepted the genus Acinetobacter after the review based on the publication 
based on Baumann’s 1968. 
 
                                 The current definition of Acinetobacter comprises gram 
negative, non fermenting strictly aerobic, non-fastidious, non motile, 
oxidase negative, catalse positive bacteria that has a DNA G+C content of 
39% to 47% 23.Now there are 26  named species and nine genomic species 
which have phenotypic similarities which are difficult to 
 differentitate24.Acinetobacter cannot be distinguished from other gram 
negative non fermenting bacteria by a definitive metabolic test while the 
species level identification for the 28 available phenotypes was proved to be 
95.6%,the recently identified genomic strains have proven to be 
ineffective25.It is now classified as the family Moraxellaceae order 
gammaproteobecteria, which include the genus Acinetobecter26.  
 
                              The isolates suspected to be Acinetobacter undergo 
routine phenotypetic test which is described by Gerner-Smid et al they are 
grown in 5% sheep blood agar at 37° and 44° C, using Hugh and leifson’s 
medium which contain 1% glucose along with gelatin  stab method to test 
for liquefaction. Then liquid media for assimilation test using carbon source 
with 0.1%concentration of malonate L-histidine t –Aconitate histamine and 
citrate are used for assimilation test Additional assimilation test such as DL 
- 4 aminobutyrate and l- phenylalanine the assimilation test are read after 1, 
2 and 6 days the growth on the agar at 37° and 44° c on the second day 
except for gelatin liquification w hic is read at a temperature of 22°C     
 
                     
         More molecular methods have been used to identify the species level of 
Acinetobacter23. 
  Amplified 16S rRNA gene restriction analysis (ARDRA). 
  High-resolution fingerprint analysis by amplified fragment length 
polymorphism (AFLP). 
  Ribotyping. 
  tRNA spacer fingerprinting. 
  Restriction analysis of the 16S–23S rRNA intergenic spacer 
Sequences. 
  Sequence analysis of the 16S–23S rRNA gene spacer region. 
  Sequencing of the rpoB (RNA polymerase β-subunit) gene and its 
flanking spacers. 
 
Natural Habitats: 
                       Acinetobacter can be isolated for all samples of soil and water 
hence called as ubiquitous organism. In a survey to study human skin flora 
of skin and mucous membrane it was found that up to 43% of the 
community had members of this organism. The most commonly found was 
A.loffii (58%), followed by A.johnsonii. The fecal carriage rate was found to 
25%, the carriage rate in the wards of the hospital was found to be much 
 higher as 75%.27 Based on the data it could be said that A.johnsonii, is found 
in soil water and on human skin. 
 
 A.lwoffii & A.radioresistense are found on human skin. The rate of 
carriage in Europe for Acinetobacter baumannii was found to be low, and in 
tropical countries, but found to be higher in countries like HongKong28 
Hence  the habitat of A.baumannii is yet to be clearly understood.     
 
 
CLINICAL MANIFESTATIONS OF ACINETOBACTER baumannii 
INFECTIONS: 
                         Acinetobacter baumannii has been associated with broad 
spectrum of diseases in varying patient outcome and severity. There are 
quite a few studies that have concluded that infection with A.baumannii  has 
a major effect on the patient outcome29,30 while the other have implied very 
little or no impact on the patients outcome following the infection.31,32 
 
 
 
 
 
 COMMUNITY-ACQUIRED PNEUMONIA:  
                        Community acquired pneumonia caused by A.baumannii has 
been found in tropical regions of Asia and Australia it has been typically 
described during the rainy season and history of alcohol abuse. The 
infection may be due to the reason that more than 10% of the population 
with the history of excess of alcohol drinking, a sever clinical course, 
secondary blood infection and mortality rate of 40 to 60%33. 
 
HOSPITAL-ACQUIRED PNEUMONIA: 
                       Ventilator associated pneumonia is the commonly linked to 
the infection caused by A.baumannii. Ventilator-associated pneumonia 
occurs after the patient has been incubated and on mechanical support for 
more than 48 hours. It is very difficult to differentiate between airway 
colonization and pneumonia. Longer period of stay in the hospital, long 
periods on mechanical ventilation and prolonged use of broad spectrum 
antibiotics are found to be the risk factors that has been implicated in 
ventilator associated pneumonia caused by A.baumannii34. 
 
 
 BLOODSTREAM INFECTION: 
                       Acinetobacter was implicated as the cause of bloodstream 
infections in more than 1.3% of the cases in a seven year review done in 
United States16. When compared between the ICU and non ICU patients the 
infected with Acinetobacter baumannii the number of infection in ICU was 
significantly higher which was 43% and 16.5% respectively. The mortality 
rate was found to be third higher after P. aeruginosa and candida spp. In the 
review mentioned above the source of infection was not explained but could 
be attributed to underling urinary tract infection pneumonia and wound 
infection. In the same review of the 102 patient who were treated for the 
infection belonged to military people who were injured in Iraq of 
Afghanistan. 
 
SKIN AND SOFT TISSUE INFECTIONS: 
                            Acinetobacter causes about 2.1% of the skin and soft 
tissue infection in the intensive care unit and it is one of the common 
pathogen that has been isolated from the burn unit patients which is very 
difficult to eradicate in these patients. The military people who were injured 
in Iraq and Afghanistan Acinetobacter was the most commonly isolated 
pathogen it was found to be of low pathogenicity in the skin and soft tissue.  
 When compared to pneumonia and other infections after the 
treatment the pathogen was not isolated in repeat cultures from the site and 
did not contribute to any persistent infection or amputation. 
 
OTHER MANIFESTATIONS: 
                          Acinetobacter is one of the pathogen that causes urinary 
tract infection it is mostly associated with catheter-associated infections and 
colonization in ICU- settings and it accounts for about 1.6% of the 
infection35.Nosocomial Meningitis is caused by more number of gram 
negative pathogens which include Acinetobacter it is often associated with 
patients who have surgery and have a external ventricular drain and the 
mortality in these cases are as high as 70%36. 
 
            Other manifestations include endocarditis involving prosthetic 
valves, endopthalmitis or keratitis following surgery and a single case of 
bloody diarrhea. 
 
 
 
 
 
 VIRULENCE POTENTIAL: 
                     Acinetobacter has several factors that contribute to its 
virulence one important factor is the outer member protein A (Omp) this 
outer membrane protein binds to the host epithelial cell and mitochondria 
after which induces mitochondria swelling it is followed by the release of 
cytochrome c, heme protein that leads to apoptosis39. The Omp A is a 
protein that is found on cell structure that also causes resistance to 
complement and biofilm formation.   
 
                    The biofilm produced by the organism play a role in survival 
inside the host the ability for the bacteria to form a biofilm helps them to 
grow persistently in unfavorable conditions and environment. The factors 
that affect its ability to produce biofilm include nutritional availability and 
presents of pili and outer membrane protein. The initiation of the biofilm 
formation is done by the pili and a protein called as biofilm associated 
protein (BAP).  
 
 
 
 
                     The pili once it gets attached to the abiotic surface it 
starts the production of microcolonies that develops into a full biofilm 
structure. The bacterial surface that contain the BAP helps in stabilization 
and maturation of the biofilm and the environmental signals like cations 
metals also play role in development of the biofilm formation and adherence 
of the surface37. 
 
                              The other protein that contribute to the virulence factor 
include phospholipase D and C the phospholipase D causes resistance for 
human serum epithelial cell invasion, and C causes toxicity in the epithelial 
cells. Though extensive research is done in the virulence factor only little is 
known about this emerging pathogen. 
 
MECHANISMS OF RESISTANCE TO SELECTED ANTIBIOTICS 
                       A wide range of antibiotic resistance mechanisms have been 
described the bacteria Acinetobacter. The Acinetobacter baumannii has 
emerged as pathogen that is resistant to beta lactams which also include 
carbapem it has the ability to respond quickly to environmental pressure.  
 
 
         In France from clinical epidemic samples A.baumannii strain, 
whole genome was sequenced compleatly38 in which 52 resistant strains 
have been identified and nearly 45 are located in the AbaR1 resistant island 
which also includes transposons insertion sequence element and the class 1 
integrons. 
 
BETA-LACTAMS: 
                  The resistances to beta-lactams in the bacteria is caused by one 
of these or combination of these factors like 
a) Hydrolysis by beta-lactamases,  
b) Alteration in penicillin binding proteins,  
c) Change in the structure and number of the porin proteins leading to 
decrease in antibiotic permeability into the cell and the up regulation 
of efflux pump that causes decrease in concentration of antibiotics in 
the bacteria. 
 
CLASS A BETA-LACTAMASES:  
                       A baumannii which belongs to class A extended spectrum 
beta-lactamases (ESBL’s) has the TEM 1 beta-lacmase has be found 
recently. The strain that has PER-1 display high penicillin resistance and 
extended spectrum cephalosporins that is ceftazidime minimum inhibitory 
 concentrations of more than 256µg /ml and cefepime 32 µg/ml but they do 
not cause resistance to carbapenems. PER-1 is prevalent in Turkey and 
Korea which has also been reported in this France, Belgium, and Bolivia. 
 
         An ESBL A. Baumannii which has CTX-M-2 has enhanced 
ability to hydrolysis cefotaxime and ceftriaxone which is epidemic in 
countries like Japan and Bolivia40 but the overall prevalence of CTX –M is 
low in the Acinetobacter sp. When compared to Enterobacteriaceae 
 
CLASS B BETA-LACTAMASES:  
                    These beta-lactams are able to hydrolysis betalactam as well as 
carbapenems with the exception of aztreonam. Class b beta-lactamases have 
a metallic iron in the active site which is zinc that acts as catalyst which is 
absent in class A and D Carbapenemases. So they are called as metallo-beta-
lactamases. IMP MBL they are found in different parts of the world and 
they are mostly detected in the class one integron though IMP MBL are not 
commonly found in Acinetobacter baumannii, several types have been 
described IMP-1, IMP-2, IMP-4, IMP-5, IMP-6 and IMP-1141. 
 
 
                            MBL isolated from Italy a pseudomonas aeruginosa 
encoded by Verona intergron has been reported as VIM-1.Acinetobacter 
baumannii which cointainsVIM-2 has been reported from Korea. The 
description of Seoul imipenemase SIM-1, a novel MBL, has also been 
reported, SIM-1 belongs to the B1 sub class. The broad spectrum SIM-1 is 
69% homology to IMP-12 MBL and 64% homology IMP-9 MBL it 
suggests that is gene cassette could have originated from In55044 
superintegron from Pseudomonas alcaligenes43.  
 
CLASS C BETA-LACTAMASES. 
                           In Acinetobacter baumannii the bla gene that codes for 
class C Betalactamases it hydrolysis penicillin and a narrow group of 
extended spectrum of cephalosporins but cannot hydrolyze cefepime or 
carbopenams. There are up to 28 variants of bla gene are listed in the gene 
bank. Like many gram negative bacteria Acinetobacter also has 
chromosomally encoded class C beta- lactamase, ampC gene, it could have 
been descended from a common beta-lactamase gene ancestry and 
Acinetobacter derived cephalosporinases called as ADC’s44 .   
 
 
 
 CLASS D BETA-LACTAMASES: 
                  The OXA beta-lactamases belong to the class D which produces 
oxacillinases and some of the OXA have the ability to hydrolyze extended 
spectrum cephalosporins but the most important are the OXA which can 
inactivate even carbapenems. They were first described in a clinical isolate 
in Scotland OXA – 23 even before the introduction of carbapenems and 
named as ARI-1 (Acinetobacter resistant to imipenem)45. Since then it has 
been discovered in many parts like England, Brazil, Singapore, Korea and 
China. 
 
      An important factor has be implicated to cabapenem resistant in 
Acinetobacter baumannii that they are associated with ISAba1 and ISAba3 
which are naturally occurring plasmids that are found in them47. These 
isolates have relatively high MIC for imipenem and Meropenem> 32µg/ml. 
Most of these oxacillinases are chromosomally mediated. The the 
carbapenem-hydrolyzing oxacillinases are thought to be chromosomally 
mediated enzymes plasmid and naturally occurring are given in table 1. 
 
 
 
 
 Table 1 
OXA carbapenemases in Acinetobacter baumannii Carbapenemase type 
OXA Carbapenemases47 
 
Carbapenemase type OXA carbapenemases 
Acquired/Chromosomal OXA-24, OXA-25, OXA-26, OXA-40, OXA-58a 
 
Plasmid OXA-23, OXA-58a 
 
Naturally occurring 
OXA-51/69 like 
OXA-64, OXA-65, OXA-66, OXA-68, OXA-70, 
OXA-71, OXA-78, OXA-79, OXA-80, OXA-82 
 
 
An OXA-58 has been described both as chromosomal and as a plasmid-
mediated carbapenemase in A. baumannii.  
   
                OXA-51/69-like betalactamase are located chromosomally in 
Acinetobacter baumannii that has been described in all the parts of the word 
and called as naturally occurring and their expression depends upon the 
presents of ISAba1.   
 CHANGES IN OMPS AND PBPS 
               In Acinetobacter baumannii other non enzynematic mechanisms 
such as change in outer membrane protein efflux pumps alteration in 
expression and affinity of penicillin binding proteins also causes both beta-
lactam and resistance to carbapenems. The resistance to imipenem and 
Meropenem has been associated with the loss of a 29-kD protein called as 
CarO48 which belongs to the OMP found only in Moraxellaceae.   
 
EFFLUX PUMPS: 
                 They are simple and single mechanism that causes resistance to 
many classes of antibiotics these pumps cause the efflux of compounds that 
are toxic to the bacterial cell which also includes antibiotics. The efflux 
pumps that are found in various species of bacteria belong to the small 
multidrug resistance superfamily the major facilitator superfamily the 
multidrug and toxic compound extrusion superfamily and the resistance-
nodulation –cell division family49.  
 
                 The efflux pump that is found in Acinetobacter baumannii 
is called as the AdeABC efflux pump they belong to the family called as the 
resistance–nodulation-cell division family. These efflux pumps efficiently 
pump antibiotics like fluro-quinolones, trimethoprim, chloramphenicol, 
 erythromycin, tetracyclines, cefotaxime and aminoglycosides by over 
expression of this efflux pump. The expression of these pumps is managed 
by a two step regulator (adeR) and sensor (adeS) system. This over 
expression is due to a single point mutation in the gene adeR adeS50. 
 
AMINOGLYCOSIDES: 
                  The presents of aminoglycosides- modifying enzyme which is 
coded by the gene present in class 1 integron is prevalent in multidrug 
resistant A baumannii. Recently strain from Japan Korea and united states 
have described 16S rRNA methlation in A baumannii (armA) they impairs 
the binding site and target sites of aminoglycosides to cause high level of 
resistance to all aminoglycosides which also include amikacin tobramycin 
and gentamicin.  
 
      With the use of PCR mapping it showed that the genes that 
encode for aminoglycosides modifying enzyme are aphA1, aphA6, aacC1, 
aacC2, aacA4, aadA1, and aadB51 along with the production of enzymes the 
AdeABC efflux pump also transport amikacin and kanamycin due to its 
hydrophilic nature but less effectively when compared to enzyme.    
 
  
 QUINOLONES: 
                    The resistance to quinolones is by modification in the structure 
of DNA-gyrase which leads to low affinity for the binding of the drug to the 
DNA complex enzyme. This modification of the structure is caused by 
mutation52 in the gene specifically in the region gyrA and parC they also 
have efflux pump which includes RND type pump and MATE pump AdeM, 
so far qnr gene which is a plasmid mediated quinolones resistance have not 
been reported in A.baumannii. 
 
TETRACYCLINES: 
                     Efflux pump and ribosomal protection causes resistance to 
tetracyclines and their derivatives. The efflux pump are coded by tet(A)- 
tet(E) till date the tet(A) and tet (B). tet (A)53 coded only for resistance 
against tetracyclines but has no resistance against minocyclines. Resistance 
to Tigecycline is conferred by AdeABC efflux pump in A.baumannii theses 
strains show threefold increase in MIC. These efflux pumps are coded by 
adeB gene and these strains are also resistant to gentamicin, levofloxacin, 
and chloramphenicol.   
 
 
 
 CARBAPENEMS: 
                       The resistance to carbapenems is caused by the production of 
beta-lactamses and also contributed to reduced affinity to PBP’S for 
carbapenems increased efflux of antibiotics decreased permeability of the 
outer membrane. In the bacteria Acinetobacter baumannii the combined 
action of AmpC betalactamase with weak carbapenemase activity and other 
may also contribute to it such as decreased production and reduced affinity 
to PBP’s and sometimes loss of OMP’s.  
 
           Most of the OXA type carbapenemases causes only reduced 
susceptibility to carbapenems when there are also the presents of secondary 
mechanism the clinical detection of   the organism producing theses 
enzymes remains to be difficult54. The chromosomal location of the gene 
that encodes contributes to their spread and also due to the increased 
selective pressure.  
 
        The carbapenemases belong to the family of beta-lactamases that 
has a very broad spectrum of which more efficient than most of the beta-
lactam-hydrolyzing enzyme and they are all highly resistant to all 
commercially found beta-lactamases inhibitors. 
  The beta-lactamases are classified on the basis of functional properties 
and molecular properties  
 
(i) The beta-lactamases were analyzed biochemically and the protein 
was isolated and by enzymatic studies to determine the hydrolysis 
and inhibitor profiles were studied. 
(ii) It was based on the homology of the amino acid  
 
       As a result four major classes where A, C and D which included 
the beta-lactamases with serine in the active serine and B which had all 
metalloenzymes with an active site zinc55.    
 
 
 
 
 
 
 
 
 
 
 Classification of carbapenemases into groups and subgroups 
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 MOLECULAR CLASS A CARBAPENEMASES 
Class A carbapenems that belong to the functional group 2f, and have 
been detected in Enterobacter cloacae, Serratia marcescens, and Klebsiella 
spp. They show reduced susceptibility to imipenem. The class A contains 
three major families which are NMC/IMI, SME, and KPC enzymes56 they 
can hydrolyze a many beta-lactams including aztreonam and carbapems, 
cephalosporins and penicillins and are all inhibited clavulante and 
tazobactam. 
 
CLASS B METALLO-_-LACTAMASES  
The metallo-beta-lactamases have the ability to hydrolyze 
carbapenems and they are also resistant to the commonly used beta-lactmase 
inhibitor but these can only be inhibited using metal ion chelators. The class 
B carbapenems have to ability to hydrolyze cephalosporins carbapenems 
and penicillin but they do not have the ability to hydrolyze aztreonam the 
principle is that the beta-lactams with Zn2+ of the active site in the enzyme, 
which can be chelated only by EDTA or any other divalent cations51. 
  
The metallo-beta-lactamases are found chromosomally in the 
prevalent species that are producing these enzyme but the most common 
families include in it which are VIM, IMP, GIM and SIM are found in 
 integron structures which becomes incorporated in the plasmids and are 
readily transferred between bacteria. 
 
CLASS D BETALACTAMASES 
                    This class of betalactamases are also called as 
oxacillinases or called as OXA type of beta-lactamases when compared to 
class A and C they all have same serine active sites but differ in amino acid 
structure. The class B betalactamases are metalo enzymes with Zn ions. 
Which is not seen in class D several class D beta-lactamases have expanded 
spectrum of hydrolysis resulting from point mutation. These genes are 
embedded into class 1 integrons which include insertion sequence and 
transpoons.  
 
                   The class D betalactamases are not inhibited by 
clavulanic acid sulbactam and tazobactum they are also not inhibited by 
EDTA. The class D betalactamases can be inhibited by NaCl in-vitro this is 
not seen in other class of beta-lactamases but the property is not clearly 
understood. 
  
 
 
 The OXA groups of carbapenems are divided into eight sub groups54  
• The first group has OXA 23 which is also called as ARI-
1(Acinetobacter resistant to imipenem) they differ by 2-5 amino acid 
other enzyme that belong to this group are OXA 27 and OXA 49. 
 
• These vary by 1-5 amino acid in their genetic sequence they contain 
OXA 24 OXA 25 OXA 26 and OXA 50. 
 
•   The third group mainly contains OXA 51 like  enzymes and the 
fourth group only has OXA 58 like cluster which also includes OXA 
64-66 OXA 68-71 and OXA 75-78.they diverge by 1-12 amino acid 
and are naturally occurring in Acinetobacter baumannii 
 
• The fifth group have chromosomally encoded enzyme which is seen 
in Klebsiella pneumoniae which are derived from shewanella algae 
which is chromosomally encoded enzyme OXA -55 and has a enzyme 
which is derived by five substitution. 
 
 
 • The sixth branch is derived from Shewannella oneidensis and differ 
by 20 substitutions   
 
• The seventh and eight branches of class D  are represented by OXA -
50 enzyme of p. aeruginosa and the OXA-60 enzymes in Ralstonia 
pickettii, they also have several variants of this enzyme the members 
of OXA-50 differ with 1-5 substitution while OXA 60 differ by 1-21 
amino acid difference.   
 
 
POLYMYXINS 
                   Polymixin E and polymixin B are used to treat the multidrug 
resistant Acinetobacter baumannii infections polymixin B resistant was 
reported by Urban et al in 2001 a sub population genetically identical clones 
which are more resistant than the parent bacteria which was called as 
heteroresistance have now been described in Acinetobacter baumannii the 
complication of these heteroresistant have to be studied from the patients 
outcome who are under the treatment of colistin the modification of the 
lipopolysaccharide that is acylation acidification and the presents of antigen 
 that interferes with binding of the drug with the cell membrane could be the 
possible mechanism for  the resistance of colistin even though it has not 
been clear54. 
 
 When compared to carbapenems the resistance to colistin is lower due 
to their infrequent use as they are reserved drugs used only for the treatment 
of carbapenem producing bacteria. There has also been treatment failure 
reports from various parts of the world about 28% of colistin resistant 
Acinetobacterbaumannii reported in Asia. 
   
            Hetro-resistance: Among the colistin resistant group of 
bacteria Acinetobacterbaumannii and followed by K.pneumoniae and 
P.aeruginosa this resistance occurs due to mutations which lead to bacterial 
cell membrane changes and specific outer membrane protein content and 
cross resistance that occur between colistin and polymixin B59.  
 
         The colistin-susceptible strains that harbouring a resistan sub-
population this is called as heteroresistance but the impact of this 
heteroresistance clinically and anitibiotic treatment strategies have yet to be 
seen. This can be prevented by using colistin as a part of combination 
therapy and also by drug interval duration and dose. 
 MONOTHERAPY: 
                     In the resent studies it has come to light that decrease in 
concentration of the drug there is re-growth of the bacteria that survive. 
This decrease in concentration is due to59. 
 
• The majority of the drug is excreated in the urine before it is 
converted into its active form. 
• The drug binds with α1-acid glycoprotein an acute phase 
protein that is found in critically ill patients that combines 
with the drug to inactivate it. 
 
                                These facts suggest that the colistin should be given as a 
part of combination to act synergistically against the pathogen and decrease 
the enzyme resistance. Now there is a compelling need in microbiology to 
perform the synergy testing methods to determine the synergistic 
combination in vitro and vivo.    
 
 
 
 
 
 OTHER ANTIBIOTICS 
                   The resistance to trimethoprime-sulfamethoxazole and 
chloramphenicol resistance have also been reported in multidrug resistant 
Acinetobacter baumannii strains. The gene encoding for the resistance for 
these drugs (dhfr &cat) have been found inside the 3´ conserved region of 
the integron which also has qac gene that confrere to resistance to 
antiseptics and sulfonamides60. The role of efflux pumps in the resistance 
against these antibiotics also could be possible.  
 
                   The presents of an intrinsic chromosomal 
cephalosporinase (AmpC) is the most common mechanism of resistance in 
Acinetobacter baumannii.62  
 
 
 
 
 
 
 
 
 MECHANISMS OF ANTIBIOTIC RESISTANCE IN 
ACINETOBACTER SPECIES 62. 
 
Mechanism                                           Acinetobacter species                
 
β-Lactamases 
AmpC cephalosporinase                                           +                                               
 
Inducible                                                                   _                                              
 
TEM                                                                          +                                               
 
SHV                                                                          +                                                
 
CTX-M                                                                      +                                               
 
PER                                                                            +                                                
 
VEB                                                                           +                                                
 
OXAa                                                                         +                                               
 
IMP                                                                             +                                               
 
VIM                                                                            +                                                 
 
SPM                                                                            _                                                   
 
GIM                                                                             _                                                   
         
PSE                                                                              _                                                  
 
GES                                                                             _                                                   
  
 
 
 
 
 
 
 Mechanism                                        Acinetobacter species               
 
 
IBC                                                                     _                                                    
 
OMP changes                                                     +                                                     
 
AMEs 
Adenylating                                                        +                                                 
 
Phosphorylating                                                 +                                                  
 
Acetylating                                                         +                                                   
 
Topoisomerase mutations 
gyrA                                                                     +                                                  
 
parC                                                                    +                                                 
 
Efflux pumps                                                       +                                                 
 
Mobile genetic elements                                      +                                                 
 
Integrons                                                              +                                                 
 
Membrane changes and resistance 
to polymyxin                                                         _                                                 
 
 
 
 
 
 
 MANAGEMENT OF ACINETOBACTER BAUMANNII: 
           Acinetobacter may colonize the skin pharynx GIT urethra 
conjunctiva and vagina so care must be taken to rule out colonization and 
environmental contamination. The colonization does not require any special 
treatment but the identification of resistance to multiple antibiotics are of at 
most important. 
 
           For the susceptible strains they have been treated with beta-
lactams mostly the third generation and extended spectrum penicillins have 
been used for the treatment. In the case of severe infection penicillin with 
beta-lactam inhibitors and cabapenem with combination with 
aminoglycosides have been used63.     
 
                     In the management of Acinenatobacter baumannii and 
Acinetobacter spp the CLSI recommends broth dilution or disk diffusion 
test these test are performed using Muller-Hinton agar or cation-adjusted 
Muller-Hinton broth direct colony suspension, equivalent to 0.5 McFarland 
standard Incubation at 35°C. They are tested against the following groups of 
drugs, penicillins, betalactamase inhibitor combinations, cephems (including 
cephalosporins I, II, III and IV), carbapenems lipopeptides, 
 Aninoglycosides, tetracycline fluoroquinolones and folate pathway 
inhibitors. 
  
GLOBAL EPIDEMIOLOGY 
                        Acinetobacter baumannii is now an emerging carbapenem 
resistant bacteria worldwide it has been shown that the percentage of 
carbapenems resistant bacteria have increased over the last ten years like 
North America, Europe and Latin America. In Europe they have been 
reported in northern parts united kingdom, Spain, Portugal,  France, Poland, 
Netherlands and Czech republic the countries from southern Europe and 
middle east include Turkey Italy, Greece, Bulgaria, United Arab Emirates, 
Iran, Iraq and Israel. 
 
                       A.baumannii is not confined to one hospital in the city it can 
occur national wide like the spread of the OXA23 clone to England the 
disseminated of multidrug resistant clone in Portugal. Intercontinental and 
international spread has also been identified between Europe and other 
places as a result of airline travel64. These events show the importance of 
screening and isolation of the patients being transferred from countries with 
high prevalence of drug resistant organism. 
                             According to the Antimicrobial SURVEILLANCE 
REPORT resistance surveillance in Europe 2012 more than half of the 
isolates of Acinetobacter baumannii resistance to carbapenems were high 
along with most cases of combined resistance to other antimicrobial groups 
the counties like Iceland, Luxembourg and Malta reported less than 10 
resistant isolates. The lowest was reported from Netherlands 1.7% and the 
highest was seen in Italy 83.1% for aminoglycosides. More than 18 
countries reported for Fluoroquinolones the least no isolates were from 
Norway and Netherlands and the maximum was seen in Greece93.1%.  
 
                For Carbapenems in the year 2012 overall 3190 were 
reported in Europe the least was reported from Norway >1 to 87.8% in Italy. 
The combination resistance was seen more common over all 4.9% was 
single drug resistance and 17% reported for two classes of drugs, the most 
common resistance was seen to fluroquinolones and combination with 
aminoglycosides or to carbapenems or both were more common.    
 
     
 
                In north America after an out-break of ESBL producing 
Klebsiella for which  imipenem was significantly used, following which  the 
infection due to carbapenems resistant A baumannii  was reported in large 
number of hospitals65 in 1991 and 1992 After which numerous out breaks 
have been reported of multi drug resistant A baumannii.  
 
            In the United States most common bacteria isolated from 
gram-negative bacilli active surveillance cultures, 1 June 2009–31 May, 
2012 Acinetobacter baumannii was one was the most common isolated 
bacteria only next to Escherichia coli, Klebsiella pneumoniae and 
Enterobacter aerogenes66. In which 44.8% of the isolates were multidrug 
resistance isolates, 33.6% were aminoglycosides 36.4% were 
betalactamases 44.1% were carbapenems and floroquinolones.  
 
          In the Middle East67 the most commonly isolated gram negative 
non fermentative organism was P. aeruginosa (72.9%), followed by A. 
baumannii (25.3%) and S. maltophilia (1.8%) was reported in March 2012. 
It was found that of the total number of the isolated Acinetobacter 
baumannii >50% of the isolates were resistant strains which showed about 
76.9% resistance to amikacin, 77.8% resistance to gentamicin, 5.4 % 
 resistance to Imipenem, 95.5% to aztreonam, 90.6% to tetracycline 95.9% to 
chloramphenicol, and 13.2% resistance to polymyxin-B.  
 
                          In India a study done over a period of one year from 
January to December 2013 from various tertiary care hospitals in Delhi and 
other parts of India was done which reviled large number of isolates that 
were multi drug resistant68. Of the total number of isolates 88.60% showed 
resistance to Cefotaxime 88.94% to amikacin 80.54% to gentamicin 
moderate number of isolates were resistant to Piperacillin tazobactam 
32.98% and also with netilmycin which was 39.04% and low number of 
isolates was found to be resistant to Imipenem 15.22% meropenum was 
found to be 7.32% and less than 2% for colistin and polymyxin B. 
 
            In a study conducted in 2010 by AIIMS it was found that 
about 17.32% of isolates was resistant to Imipenem and in Vellore by 
Anitha et al resistance to carbapenems was reported to be 96.6% and in 
Mumbai that showed 29% was resistant to Imipenem.    
 
 
 
 GLOBAL EPIDEMIOLOGY OF CARBAPENEM RESISTANCE IN 
ACINETOBACTER BAUMANNII;    
                 The exposure of Acinetobacter baumannii to various groups of 
drugs in the intensive care units gradually, due to selective pressure has led 
to the prevalence of resistant to carbapenems worldwide. The relevant 
carbapenamases gene in Acinetobacter baumannii such as 
cephalosposporianases and oxacillinases have all been described in the 
bacteria71   
Table 2 Genes of carbapenemase production. 
Enzyme Described in 
association with 
Isolated in 
IMP-1 Class 1 integron Italy, Japan, India  
N.Korea 
IMP-2 Class 1 integron Italy 
IMP-4 Class 1 integron Singapore, Hong Kong 
IMP-5 Class 1 integron Portugal 
VIM-2 Class 1 integron North Korea 
VIM-1 Class 1 integron Greece 
VIM-3 Class 1 integron Taiwan 
VIM-4 Class 1 integron Greece 
SIM-1 Class 1 integron China, South Korea 
 Enzyme Described in 
association with 
Isolated in 
NDM-1 Chromosomal/ISAbal 
25; plasmid 
India Germany, china 
Bangladesh, Belgium.  
NDM-2 chromosome Egypt Israel arab 
emirates  
OXA-23 Chromosome/plasmid UK,USA, France, brazil 
Italy Greece  
OXA-24/40 Chromosome/plasmid Portugal, Spain, Italy, 
Greece, UK, USA 
Spain 
OXA 58 Chromosomal/plasmid France, Spain, Italy, 
Greece, UK, Austria, 
Romania, Iraq, Kuwait, 
Lebanon, Turkey 
 
                         The OXA 51- like  enzyme cluster vary from other OXA 
type of  carbapenemases as it is chromosomally located also inherent in 
Acinetobacter baumannii55 but its activity depends on the presence the IS 
element. The most commonly found type of OXA carbapenemase which is 
blaoxa-24-like which similar to OXA-23 like enzyme this gene was located on 
plasmid. The blaOXA-58-like is a plasmid mediated and has been reported in 
many hospitals out breaks and found with the association of ISAba2, IS18 
 element in all strain which suggested that this might been acquired by 
horizontal transfer of gene. 
 
Combination therapy. 
                 The combination therapy for the treatment of gram negative 
bacteria was due to the following reasons 
• Delay or prevent the occurrence of resistance in the bacterial strain 
due to antibiotic therapy70. 
 
• To improve the clinical outcome for the patient by using the 
synergistic effect. 
 
• To increase the impirical coverage that is provided by the different 
spectrum of activity of the drugs. 
 
               Even though there is a strong appeal for this approach there are 
only few strong evidence to support for the treatment of drug  resistant 
gram negative infections and the addition of the second drug also cause 
increase in drug resistance  increase in costs and adverse effect like for 
example nephrotoxicity related to aminoglycosides all have be well noted 
 
                          There are some studies that have shown decrease in mortality in 
patients who have treated with combination therapy in a retrospective study 
conducted by in 281 intensive care units between combination therapy with 
betalactams along with aminoglycosides /macrolites /fluroquinolones 
compared with betalactam monotheraphy which resulted in decreased 
mortality of 36% and 29%. When a combination therapy can be prescribed 
the second antimicrobial agent that has been chosen should have activity 
against the organism which is potentially resistant to the beta-lactam. The 
selection should be based upon70  
 Use of  epidemiology of the local susceptibility pattern. 
 
                       Individualization of combination therapy based on patient 
characteristics because as patients differ with regard to preexisting medical 
conditions, severity of illness, nature of infection, previous antibiotic and 
hospital exposure, presence of indwelling catheters, and colonization with 
antibiotic-resistant organisms. 
 
Methods to test for antibiotic drug synergy  
             There are many methods use in-vitro to test the synergy, the 
methods described are modifications of the E-test, checkerboard assay and 
time-kill assay.  
 Time-kill assay: 
          Here the bacteria is allowed to grow in a liquid medium in which the 
test antimicrobial agent is incorporated and the viability of the bacteria is 
checked at different interval the test is done by the addition of the second 
drug intended to be used in the combination therapy and other with a single 
drug71. At defined time intervals specific amount of broth is sub-cultured on 
to the agar medium and the number of colonies are counted. It is found to 
synergy if there is decrease in 2 log 10 between drug combination and the 
single drug. 
 
Checkerboard assay: 
                             Here in a 96 well micro-plate the mic the MIC if test drug 
A the MIC of test drug B and MIC of the combination (A+B) are 
determined the total fractional inhibitory concentration (ΣFIC) is calculated 
which is the interaction between drugs A and B  ΣFIC = FIC of drug-A + 
FIC of drug-B; where FIC of drug-A = MIC of drug A / MIC of (A + B) 
combination and FIC of drug-B = MIC of drug B / MIC of (A + B). The 
ΣFIC values ≤ 0.5 is interpreted as synergy, 0.5 - 4 as indifference and the 
values > 4 indicate antagonism72.  
 
 
 E-test methods 
                         Drug synergy detection in combination using   
Epsilometer strips can be done by three different methods73  
1. Fixed ratio method: in this method the test organism is streaked in a 
Petri dish and the e strip of drug a is placed in it and the MIC are 
marked using a sterile needle then incubated for an hour then the e 
strip A is replaced by the E strip containing the B drug such a way 
that the MIC of drug A and B coincide with each other then the plate 
is incubated for 18 hours and readings are taken. 
 
2. The second method is done by placing the two E strips at right angle 
to one another at the same time in such a way that the MIC intersect 
with each other and the readings are taken after 18-24 hours like the 
previous method. 
 
 
3. The third method: in this method one of the drugs is dissolved in t 
media (most potent drug) in a fixed concentration and the E strip for 
the second drug is placed over it.  
 
  In all the three methods the results can be calculated similar to 
Checkerboard assay by calculating the ΣFIC value. 
 
Different Synergy Testing Method’s   Performance: 
              The time kill assay method is considered to be the better among the 
in-vitro methods to test for synergy testing and is considered to be the gold 
standard. The E test methods are considered to be the most easy to perform 
and also the results can be provided earlier and the third method in which 
the drug is incorporated in the media has proved to show correlation with 
time kill assay but the Epsilometer strips are expensive to be used in routine 
diagnostic work. The checker board assay provides reliable results, the 
checkerboard assay and time-kill assay both faces the disadvantage of being 
too labor intensive for routine diagnostic work. The advantage over time kill 
assay is that can detect antagonism better than tike kill assay and some 
studies have shown good correlation with clinical outcome74. 
 
Animal models: 
                           Animal model serves as a guide to test the efficacy in vitro 
combinations. In the animal model the results of the in vitro test have be 
contrast to the in-vivo test, in the guinea pig model tested for Acinetobacter 
baumanni Imipenem sensitive strains it was found to be less effective when 
 it was treated with Imipenem and amikacin than in mono therapy of the 
same antibiotics. Similarly the combination of Imipenem with levofloxacin 
combination did not achieve bactericidal activity in animal model. Similarly 
it was seen in the combination of amikacin and doxycycline75.    
 
                               The combination of rifampin with Imipenem tobramycin 
or colistin demonstrated in mouse pneumonia models with Imipenem 
resistant strains showed good results when compared to Imipenem when 
compared to Sulbactum. In an inter-peritoneal infection high survival rate 
was observed in the combination of meropenem and Sulbactum than in 
monotherapy of both the drugs76. 
 
                              Rifampin had shown good efficacy in different animal 
models with various drug combinations and the results of colistin with 
combination of other drugs was not as effective in both pneumonia and 
endocarditids models77. 
 
Clinical studies: 
                         During the past two decade treatment of these multi-drug 
resistant Acinetobacter baumannii have proven to be difficult and there is 
still no prospective studies to guide for the combination treatment for this 
 organism, on a study done with critically ill patients only four patients 
showed improvent with the combination of carbapenem and Sulbactum and 
the study concluded as Sulbactum could provide an alternative in cases 
where tigecycline and colistin are not available78. 
 
             For the treatment of meningitis caused by multidrug resistant 
Acinetobacter baumannii, combination of amikacin and colistin and 
concluded that lack of newer agents could lead to difficulty in treatment if 
resistance may develops for combination of drugs also79. Though several 
articles has shown positive results with rifampin and Imipenem combination 
there also some studies that has shown negative results with the same 
combination.    
 
  
      
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_                4.  MATERIALS & METHODS 
 
 MATERIALS AND METHODS 
 
STUDY PERIOD:  April 2013 to July 2014. 
 
STUDY TYPE: Prospective and descriptive study. 
 
SAMPLE SIZE:  77 
                                      n=4pq/d2 
                                                n = required sample size  
                                                p=expected prevalence 
                                                q=100-p 
                                                d= degree of prevalence          
                                                 n = 4 × 5.1× (100-5.1) / 5 2 
                                                               =77.43 
 
STUDY POPUPLATION: 
Among the in clinical isolates obtained from both the in-patients and out-
patients in out hospital who visited our hospital during the duration of the 
study. 
 
 
 Inclusion criteria: 
All multi and pan drug resistant Acinetobater sp isolates were included in 
the study. 
 
Exclusion criteria: 
All susceptible strains of Acinetobacter sp were not included.  
 
Ethics approval: 
Approval was obtained from the Institutional Ethics committee before the 
start of the study. It was renewed during the period of the study. 
 
 
   
 
 
 
 
 
  STUDY DESIGN:  
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 Figure 1 
DISTRIBUTION OF BACTERIAL ISOLATES IN VARIOUS 
SAMPLES 
 
 
Identification of the bacteria by phenotypic methods: 
The isolates from the clinical sample underwent various phenotypic 
test based on the method described be Gerner smidt the isolates. In the 
isolates the test like gram stain, oxidase test, motility and growth in blood 
agar and Mac Conkey Agar was done and the organism which was gram 
negative oxidase negative and non motile underwent other test for 
66%
24%
8%
2%
Sales
Respiratory Tract Samples Wound swab Blood  urine
 identification which in brief included 1% glucose containing media in Hugh 
and leifson’s medium, gelatin liquefaction and assimilation tests which 
contained 0.1% t-Aconitate, L-histidine, malonate and citrate also 
susceptibility to penicillin G (10µg) and chloramphenicol (30µg). 
 
The isolates were also identified using VITEK automated microbial 
identification system. It was done by isolating a pure culture and suspending 
2-3 colonies in saline, it is to  be prepared to match 0.5 Mc Farland standard 
and using the identification for gram negative bacteria card GN (gram 
negative) they were identified. 
 
                 Based on the phenotypic test done the Acinenatobacter species 
were differentiated, based on the table.  
 
 
 
 
 Table 3 Phenotypic characters of Acinetobacter species.  
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 ANTIBIOTIC SUSCEPTIBILITY TESTING: 
        The antimicrobial susceptibility tests for the Acinetobacter sp was done 
by Kirby-Bauer disc diffusion method as per the Clinical and Laboratory 
Standards Institute (CLSI-2013) guidelines using Muller- Hinton (MH) 
agar. The results were also interpreted as per the same guidelines. The 
following drugs were all tested and they were also tested by vitek automated 
system with the card AST-N281 Gram negative card susceptibility card to 
which 145µl of 0.5 Macfarland standard of the coloney suspention is added 
to 3 ml of the saline. Then by broth dilution in the machine the susceptibility 
was found.  
 
Table 4 Break points for various antibiotics. 
Antimicrobial agent 
(µg)
Zone size (mm) 
Piperacillin 100 >21 
Ticarcillin  75 >20 
Ampicillin-sulbactam 
10
>15 
Piperacillin-tazobactam 
100
>21 
 Antimicrobial agent 
(µg)
Zone size (mm) 
Ticarcillin-clavulani 
acid 75
>20 
Ceftazidime 30 >18 
 Cefepime 30 >18 
Ceftriaxone 30 >21 
Imipenem 10 >16 
Meropenem 10 >16 
 Polymyxin B MIC<2 
Colistin MIC <2 
Gentamicin  10 >15 
 Amikacin 30 >17 
 Tetracycline 30 >15 
 Doxycycline 30 >13 
 Ciprofloxacin 5 >21 
Levofloxacin 5 >17 
Trimethoprim-
sulfamethoxazole 
            >16 
 
 
 Screening test for carbapenemase detection: 
• The isolates that produce carbapenemase are found to be resistant to 
carbapenems and also to other beta lactum antibiotics.  
 
• The carbapenemase producing isolates show intermediate or 
resistance to one more carbapenems and also test resistant to one or 
more agents of class III (ceftriaxone Ceftazidime cefoperazone 
Cefotaxime)  
 
 
• In Acinetobacter sp, It can also be identified by the performing broth 
dilution which have Imipenem >8 µg /ml. 
 
CONFIRMATORY TEST FOR CARBAPENEMASES. 
               As per CLSI the confirmatory test which is done for the isolates 
which produces carbapenemase is Modified Hodge Test. It is based on the 
principle that the carbapenemase enzyme produced by the strain will diffuse 
into the culture media and the sensitive indicator strain will still grow even 
in the presents of Imipenem near the strain producing an indentation.  
 
 Procedure: 
The ATCC E coli strain was inoculated on the surface of Mueller 
Hinton plate from a fresh preparation of 0.5 Mc Farland suspension. 
 
           In the center of the inoculated plate Meropenem (10µg) disc were 
placed then the test organism is streaked from the edge of the disc in a 
straight line. The plates were then incubated in 37°C for 16-24 hours 
 
Interpretation 
                    The plate was then examined after incubation for the clover leaf 
pattern at the point of intersection of the test strain and the ATCC strain, the 
results were interpreted as positive or negative. 
                    If the ATCC organism has a clover leaf like indentation along 
the growth of the test organism in the disc diffusion zone, then called as 
Modified Hodge Test positive. 
 
 
 
 DETECTION OF CLASS A CARBAPENEMASE 
Boronic acid inhibition test:  
The test organism was prepared to 0.5 Mc Farland suspension and lawn 
culture was inoculated on MHA plate, then either of Imipenem/ meropenem/ 
ertapenem disc and another disc was placed along with it 400 µg 
phenylboronic acid in the inoculated Muller Hinton agar plate.  
The plates are incubate at 37°C for 18-24 hours 
 
Interpretation   
Of the both antibiotic tested in combination with phyneyboronic acid 
the zone difference is greater than 5 it was interpreted as positive for the 
production of class A carbapenemase. 
 
DETECTION OF CLASS B CARBAPENEMASE 
Combined disk test ( EDTA disk enhanced test). 
Principle: in the presents of Ethylenediaminetetraacetic acid (EDTA) the 
metallo beta-lactamase enzyme is inhibited.    
 
 Prepatration of EDTA stock solution 
EDTA 0.5M solution was prepared by dissolving 186.1 g of disodium 
EEDTA.2H2O in 1000ml of distilled water and pH of 8.0 and it was 
sterilized by autoclaving 
 
The test strain suspension was made with 0.5 Mc Farland and it is spread 
over a Mueller Hinton Agar plate then two antibiotic disc one was 
Imipenem (10µg) and the other Imipenem with EDTA added to the disc. 
Then the plates are incubated at 35°C for 16 to 20 hours. 
 
Interpretation   
A zone size of greater than 5 mm between the two disc (EDTA combination 
> than the Imipenem disk) is conformation for the production of MBL 
production. 
 
 
 
 DNA EXTRACTION FOR POLYMERASE CHAIN 
REACTION (PCR) 
Preparation of isolates  
The isolates from which the DNA where extracted was first inoculated in 
Luria-Bertani medium (broth) which contained for 1000 ml of distilled 
water 5 grams of sodium chloride 5grams of yeast extract and 10 grams of 
trypton. The broth was incubated overnight and two to three ml was used for 
extraction 
Table 5 Composition of Luria Bertani broth. 
 
S. No                INGREDIENTS    QUANTITY 
   
 1. 
 
Tryptone 1.0% [w/v] 
 
10 g 
  
  2. 
 
Yeast extract 0.5% [w/v] 
            
            5 g 
  
  3. 
 
NaCl 0.5% [w/v] 
 
            5 g 
  
  4. 
 
Water 
 
    1000 ml 
 
 DNA Extraction Procedure 
  
 
  
 
          
  
 
 
 
 
 
 
 
 
 
 
2 ml aliquots of the test organism in LB broth was centrifuged 
at 5000 revolutions per minute (RPM) for 10 minutes 
                  Pellets were re‐suspended in 100 µl of sterile distilled water 
Cooled centrifuged @ 5000 RPM for 10 minutes 
Then kept in dry bath@ 95°C for 20 minutes
 
The supernatant was used for PCR, the extracted 
DNA are stored @ ‐20°C
 PCR for the detection of OXA Genes:  
                PCR was performed for 61 the isolates which are phenotypically 
confirmed to express c carbapenemase. 
The primers used were obtained from Sigma Aldrich, Mumbai, which were 
based on reference article from a previous study. The primers used were 
tabulated below 
 
Table 6 Primers used for the PCR extraction. 
S.no Name Sequence(5′-3′) Amplicon 
size (bp) 
1 OXA-51-like F- TAA TGC TTT GAT CGG CCT TG 
R- TGG ATT GCA CTT CAT CTT GG 
353 
2 OXA-23 F- GAT CGG ATT GGA GAA CCA 
GA 
R-  ATT TCT GAC CGC ATT TCC AT 
501 
3 OXA-24 F- GGT TAG TTG GCC CCC TTA AA 
R- AGT TGA GCG AAA GGA TT 
246 
4 OXA-58 F- AAG TAT TGG GGC TTG TGT TG 
R-  CCC CTC TGC GCT CTA CAT  
599 
 
 Reaction mixture: 
                Each single reaction mixture (25µl) contained 5 µl of DNA 
suspension, 15pmol of each primer (Sigma- Aldrich, Mumbai), 10mM 
dNTPs, 1 U Taq DNA polymerase, 25mM MgCl2 and 2.5 µl of 10 x Taq 
buffer. 
 
POLYMERASE CHAIN REACTION: 
                     The PCR was performed by conventional method using a 
thero-cyler, under the following conditions, which were same for all the four 
genes except the Annealing temperature alone was different for each of the 
different set of primers that are given in the table below. 
 
Initial denaturation at 94°C for 5 minutes, 30 cycles of 94°C for 25 
seconds, Annealing temperature based on the gene which is amplified and 
extension at 72°C for 50 seconds, and a final elongation at 72°C for 6 
minutes 
 
 
 Table 7 Temperature used in thermocycler for PCR amplification.  
 
NAME Denaturation 
temperature 
Annealing 
temperature 
Extension 
temperature 
OXA-51-like 94°C 51°C 72°C 
OXA-23 94°C 58°C 72°C 
OXA-24 94°C 58°C 72°C 
OXA-58 94°C 59°C 72°C 
 
              The products after amplification are stored at -20°C until they were 
subjected to agarose gel electrophoresis. 
 
AGAROSE GEL ELECTROPHORESIS: 
               The amplified product are visualized by use of agrose gel 
electrophoresis, the agrose gel was prepared to a ratio of 1% by adding 
agrose gel powder with tris borate EDTA (TBE) buffer. This solution was 
heated in microwave till it becomes a clear solution and followed by the 
 addition of Ethidium bromide to visualize the amplified DNA under UV 
light.              
 
             A 100 base pair ladder was used as the molecular marked to 
measure the amplified product from the PCR in the first well and the rest of 
the wells had 5µl of the amplified product along with 3 µl of the loading dye 
from Sigma Aldrich was used to visually see the movement of the product. 
The gel electrophoresis was performed by placing the gel in an 
electrophoresis tank containing tris borate EDTA (TBE) buffer at 74 volts 
for 45 minutes.   
 
 
Interpretation: 
The ethidium bromide was used to stain the amplified DNA for 
visualization under UV illumination. Then images of the gel are captured by 
Gel doc. The presence of the amplified DNA fragments of the OXA genes is 
confirmed by the formation of bands corresponding to their molecular 
weight and a 100bp ladder that was used for this purpose.  
 
 
 
 DRUG SYNERGY TESTING 
Checkerboard method: 
               A standard 96 well plate was used to perform the drug 
synergy testing and dugs Rifampin Amikacin Colistin and Ciprofloxacin 
from Sigma Chemical Co and Imipenem from GlaxoSmithKline (GSK) and 
sulbactam from  was used they were stored in 2- 8°C until use. 
                       The drug solution was prepared by using the appropriate 
solvent and solution as per CLSI guidelines before the test was performed  
 
Table 8 Solvents and Solutions used for Antibiotics. 
Antibiotics Solvent Solution 
Amikacin Water Water 
Ciprofloxacin   Water Water 
Colistin Water Water 
Imipenem  Phosphate buffer 
solution pH 7.2,0.01 
mol/L 
Phosphate buffer 
solution pH 7.2,0.01 
mol/L 
Rifampin 
Methanol 
0.1 M phosphate buffer 
ph 7.4 +0.45%sodiu 
dodecyl sulfonate 
Sulbactam  Water Water 
                     The drugs were taken and dissolved and diluted in the 
appropriate solution and further diluted by doubling dilution method.The 
fresh grown isolate of Acinetobacter baumannii was taken from MHA and 
using direct colony suspension was taken in saline and a standard 
suspension of 0.5 Mcfarland standard is prepared, then in double strength 
Mueller Hinton broth 25 times so the number of bacteria equal to ~3 X 
105CFU/ml 
 
Method 
 
1. Except the row 1, in each well 50µl drug A is added to each well from 
higher to lower concentration. 
 
 
2. Except the column 1 in each well 50µl of drug B is added from higher 
to lower concentration. 
 
 
 
  
                                                                                                                                    
 
 
 
 Table 9 Arrangement of antibiotic concentration in checker board. 
 
 
 
Then 100µl of the inoculum is added to each well and the control well A1 
(no drug) 
 
 
 
Then the plate is gently shaken to mix the drug and inoculum and the plate 
is kept for incubation 
 
 
 
 
 (A1 ) Drug A 
64mg/ml 
Drug  A 
32 mg/ml  
Drug A 
16mg/ml 
Drug A 
8 mg/ml 
Drug B 
2mg/ml 
    
Drug B 
1mg/ml 
    
Drug B 
0.5mg/ml 
    
    
Interpretation:  
             After twenty four hours of incubation at 37°C the results are 
read visually by looking for turbidity if the growth of the micro-organism in 
the plate and the results are noted. 
 
           The MIC of the combination (A+B) are determined the total 
fractional inhibitory concentration (ΣFIC) is calculated which is the 
interaction between drugs A and B ΣFIC = FIC of drug-A + FIC of drug-B; 
where FIC of drug-A = MIC of drug A / MIC of (A + B) combination and 
FIC of drug-B = MIC of drug B / MIC of (B + A). The ΣFIC values ≤ 0.5 is 
interpreted as synergy, 0.5 - 4 as indifference and the values > 4 indicate 
antagonism.  
 
 
 
 
 
 
 
 
 Table 10 model of micro-titer plate used for drug synergy testing. 
 
 
MIC of drug A(colistin) = 64 
MIC of drug B (imipenem or rifampin or ciprofloxin or sulbactum ) = 2 
MIC of drug A+B = 0.5 
MIC of drug B+A =32 
 
 
 
Drug B 
D
ru
g 
A
 
control 64 mg 32 mg 16 mg 8 mg 
2 mg No growth No growth No growth No growth 
1 mg No growth No growth growth Growth 
0.5 No growth growth growth Growth 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 5.  RESULTS 
 
 RESULTS 
 
 During the study period 6.8% of the total positive sample belonged 
Acinetobacter sp in our lab, which was next only to Escherichia coli 
(64.89%)Pseudomonas aeruginosa(9.8) candida(9.6) kiebsiella 
pneumoniae(8.6) and Staphyloccus aureus(7.6) in our lab. Which were 
identified based on colony morphology pale lactose fermenting colony on 
MacConkey agar gram negative oxidase negative nonmotile bacteria figure 
shown below .  
Figure 2  growth of Acinetobacter on Mac-agar. 
 
 
 
 The total number of Acinetobacter sp which was isolated in the lab was 
found to be 162 
The prevalence of each species of Acinetobacter based on the species were 
as follows 
Table 11 Distribution of various samples from which Acinetobacter was 
isolated. 
Organism  Number 
Acinetobacter baumannii 145 
Acinetobacter species  13 
Acinetobacter loffii 3 
Acinetobacter haemolyticus 2 
Total  162 
 
                        Of total number of Acinetobacter Sp 58.02% were 
carbapenem resistant strains and they all belonged to Acinetobacter 
baumannii. 
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                        Of the carbapenems resistant strain obtained it was 
found that 73% if the isolates were multi drug resistant and were only 
sensitive to colistin and one other group of drug (Tigecycline or 
trimethprime/sulfamethoxazole) and only 2 isolates were resistant to all 
drugs pan drug resistant.  
 
                        For all the strains that were suspected to screening test 
(Modified Hodge Test) was done and then confirmatory test was also done 
for strains  of the total 162 samples 94 samples were carbapenemase 
producing strains the Modified Hodge was done. 
 
In the 94(resistant to carbapenems group of drugs) strains which 
tested for carbapenemase production 100% were positive by Modified 
Hodge test and only 18.08% were positive by EDTA disk enhanced test(for 
group A) and only 2.12% by  boronic acid test. 
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Figure 4. Modified hodge test. 
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 Table12.DISTRIBUTION OF GENOTYPES AMONG THE 
ISOLATES 
S.NO OXA-TYPE TOTAL no. of 
isolates tested 
NO. OF POSITIVE 
ISOLATES 
1 OXA-51 72 72 
2 OXA-23 72 67 
3 OXA-24 72 00 
4 OXA-58 72 00 
 
Of the total number isolates tested all were positive for the OXA 51 and 
OXA 23 was positive for 67 of the 72 isolates tested.OXA 51 was positive 
in all isolates conforming the identity. 
 The genes OXA 24 and OXA 58 was absent in all the strains tested.  
  
Drug synergy test. 
                        In random 10 isolates were take which were positive by 
modified Hodge Test and susceptible only to colistin was taken and 
underwent drug synergy test by checker board method with Rifampin 
amikacin sulbactam ciprofloxacin and Imipenem in combination with 
colistin. 
 
                       The results were interpreted as synergy indifferent and 
antagonistic based on the∑ FIC values calculated  
 
That is if the ΣFIC values 
• ≤ 0.5 is interpreted as synergy 
• 0.5 - 4 as indifference  
• the values > 4 indicate antagonism.  
 
 
 
 
 
 Table 12 Combination of colistin with sulbactam 
 
Isolate  ∑Fic Interpretation 
Isolate 1 0.615 Indifferent 
Isolate 2 0.725 Indifferent 
Isolate 3 0.85 Indifferent 
Isolate 4  0.091 Synergy 
Isolate 5  0.122 Synergy 
Isolate 6 0.185 Synergy 
Isolate 7 0.122 Synergy 
Isolate 8 0.56 Indifferent 
Isolate 9 0.075 synergy 
Isolate 10 Developed complete resistance 
 
That is if the ΣFIC values 
• ≤ 0.5 is interpreted as synergy 
• 0.5 - 4 as indifference  
• the values > 4 indicate antagonism.  
 
 Table 13  Combination of colistin with rifampin 
 
Isolate  ∑Fic  interpretation 
Isolate 1 0.455 synergy 
Isolate 2 0.832 indifferent 
Isolate 3 0.291 synergy 
Isolate 4  0.787 indifferent 
Isolate 5  0.437 synergy 
Isolate 6 0.490 synergy 
Isolate 7 0.483 synergy 
Isolate 8 0.479 synergy 
Isolate 9 0.093 synergy 
Isolate 10 0.398 synergy 
 
the ΣFIC values 
• ≤ 0.5 is interpreted as synergy,  
• 0.5 - 4 as indifference  
• the values > 4 indicate antagonism.  
 
 Table 14 Combination of colistin with ciprofloxacin 
 
Isolate  ∑Fic  interpretation 
Isolate 1 0.728 indifferent 
Isolate 2 0566 indifferent 
Isolate 3 0.66 indifferent 
Isolate 4  0.66 indifferent 
Isolate 5  0.66 indifferent 
Isolate 6 0.83 indifferent 
Isolate 7 0.389 synergy 
Isolate 8 0842 indifferent 
Isolate 9 0.615 indifferent 
Isolate 10 1.00 indifferent 
 
the ΣFIC values 
• ≤ 0.5 is interpreted as synergy,  
• 0.5 - 4 as indifference  
• The values > 4 indicate antagonism.  
 
 Table 15 Combination of colistin with imipenem 
 
Isolate  ∑Fic  interpretation 
Isolate 1 0.122 synergy 
Isolate 2 0.310 synergy 
Isolate 3 0.56 indifferent 
Isolate 4  0.185 synergy 
Isolate 5  0.067 synergy 
Isolate 6 0.56 indifferent 
Isolate 7 0.122 synergy 
Isolate 8 0.185 synergy 
Isolate 9 0.125 synergy 
Isolate 10 Developed complete resistance   
 
the ΣFIC values 
• ≤ 0.5 is interpreted as synergy,  
• 0.5 - 4 as indifference  
• the values > 4 indicate antagonism.  
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             In sulbactam combination 5 isolates showed synergy while 
four remained indifference. As the test with sulbactam and imipenem was 
done last isolate no.10 developed resistance to colistin so the results could 
not be determined. 
 
                     The combination of ciprofloxacin and colistin showed the least 
effect as only one showed synergy and the rest of the isolates were 
indifferent. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                         6.  DISCUSSION 
 
  
DISCUSSION 
              The genus Acinetobacter which is a gram negative nonmotile 
nonfermenting coccobacilli that has developed into a significant pathogen in 
the healthcare institution. They mostly infect the critically ill patients in the 
intensive care units in the last 20 years it has emerged as deadly pathogen 
with their ability to acquire resistance, making it one of the most threatening 
bacteria in the antibiotic era. 
 
                          In our study the prevalence of the pathogen was found to be 
6.8%which was next only to other most common pathogen like Escherichia 
coli (64.89%) Pseudomonas aeruginosa(9.8)  candida (9.6)  kiebsiella 
pneumoniae (8.6%) and Staphyloccus aureus(7.6) in our lab. This was 
found to slightly lower when compared to study done in north India by 
Namita Jaggi et al80 (7.9%) but few reports indicated less prevalence in 
India (3.6%) and abroad (<1%), very high prevelance was observed in 
USA67 (15%) . 
 
                                The most common site of isolation of the pathogen was 
found to be respiratory tract (66%) samples and was followed by wound 
swab (24%) and blood (8%) 80 in our study similar pattern was observed in 
other studies (56.9%). A study from Delhi68 observed that most of the 
Acinetobacter were from wound however major source of this bacteria was 
respiratory tract in the western countries82.  
 
                Acinetobacter baumannii has emerged as one of the 
important pathogen due to its ability to resist beta-lactams, including 
carbapenems by various antimicrobial resistance mechanisms. In this study 
about 58.02% of the strains were carbapenems resistant. Other studies from 
North and South India (90%) reported higher incidence of carbapenem 
resistance, however very low incidence was reported from AIIMS in 2010. 
    
                        Higher incidence of carbapenem resistancewere reported 
from countries like Greece and Italy (>90%)81  USA (44.8%) and Middle 
East (25.3%)67. 
  
                         All isolates of Acinetobacter baumannii in our study were 
sensitive to colistin and polymixin B majority of the isolates (76%) were 
sensitive to Tigecycline. Susceptibility to Amikacin chloramphenicol 
ofloxacin co-trimoxazole was all less than 20%. 
              Multidrug resistant organism is defined as an isolate that is 
not susceptible to one or more agents in at least three antimicrobial 
categories. Multidrug resistance of 73% was observed in our study which 
was higher than reports from Delhi (41.5%)68 multidrug resistance incidence 
in Acinetobacter baumannii isolates from developed countries were less 
example 21% in usa and <5% in Norway80. 
     
             Pandrug resistance is defined as non-susceptibility to all 
agents in all antimicrobial categories for the isolate. Pandrug resistance was 
found to be <1% of our isolates which was less than other studies from India 
(3.5%) and West (<4%)80.   
 
            Out of 58.02% of carbapenem isolates of Acinetobacter 
baumannii in our study Modifed hodge test was positive in all isolates 
similarly finding to modified hodge test positive was observed by Aparna 
Shivaprasad82 et al. Mahajan G et al found only 46.7%. This result indicates 
 the probability of non existence of Nonenzymatic causes of carbapenem 
resistant example efflux pump in our study. 
 
             EDTA disk enhanced test is used to identify 
metalobetalactamases production in carbapenem resistant bacteria among 
the 72 isolates carbapenems resistant isolates in our study were positive by 
18.08% EDTA disk enhancement test indicating the production of beta 
lactamase higher MBL production rate 67.5 % was observed in other 
studies83. 
  
            Boronic acid inhibition test is used for the identification of 
AmpC production among the carbapenem resistant isolates 2.12% of the 
isolates were positive which was lower in other studies which observed at 
16%.   
 
MOLECULAR EPIDEMIOLGY OF CARBAPENEMASES  
                        The beta-lactamases are classified into 4 different molecular 
groups A, B, C and D based on the amino acid sequence. The class D beta-
lactamases referred to as oxacillinases as the can hydrolysis oxacillin the 
 first reported class D beta-lactamases was seen in Acinetobacter baumannii 
called as OXA 23 also know as ARI-1 A. baumannii and A. radioresistens 
both have been known to possess class D betalactamase naturally and 
Acinetobacter species may be a reservoir for class D genes. 
 
                         From various geographic areas OXA 51 was isolated from 
Acinetobacter baumannii and were chromosomally located and found to be  
intrinsic to this species.    
             In our study the gene OXA 51 was found in 100% of the 
isolates. The OXA 51 which chromosomally located in Acinetobacter 
baumannii is naturally occurring in this organism. This has been reported in 
various article and studies all over the word including India. OXA 51 
present inherently in all Acinetobacter baumannii was identified in all our 
isolates conforming the identity of the Acinetobacter baumannii isolates. 
 
             The gene OXA 23 was found in 63 isolates (93.05%)  and 
also found to be co-existing with OXA 51 In a similar study by Amudhan 
SM et al in 2011 found OXA 23 in 89.09% of their isolates, presents of 
OXA 23 and it co-existed with OXA 51 in 83% of their isolates84. In some 
the carbapenem resistant isolates (20.89%) of Acinetobacter baumannii both 
 OXA 23 and MBL were seen indicating more than one mechanism of 
resistance. 
 
             The gene OXA 24 and 58 were not found in any of our 
isolates where as Amudhan et al observed in only of their isolates carrying 
OXA 24 and OXA 58. In a similar study from North India by Niranjan D 
K85  et al in the year 2013 OXA 58 and OXA 24 were mot present in their 
isolates. In all the above studies showed that OXA 51 and OXA 23 are the 
most prevalent OXA types in Acinetobacter baumannii. 
 
Drug synergy testing: 
                  Earlier Acinetobacterbaumannii infections have been 
treated with mostly third generation cephalosporins and extended spectrum 
penicillins have been used for the treatment. In the case of severe infection 
penicillin with beta-lactam inhibitors and cabapenem with combination with 
aminoglycosides have been used. At the end of the last century 
Acinetobacter and other bacteria became associated with carbapenemase 
production and were resistant to two or three group of drugs including 
carbapenems. polymixins are only group of drugs that are used for its 
treatment of such isolates. 
  
                 In last few years antibiotic combination has been proposed 
for the treatment and management of these infection caused by such 
organisms,In combination therapy the right combination of the drugs is very 
important and also determining the dose of both the main drug and the 
adjuvant drug to achieve the PK/PD so as to achieve the maximum 
efficiency and decrease the chance of resistance and to decrease the toxicity.    
             Combination of colistin with sulbactam showed 55.55% (5/9) 
synergy in our study which was similar to those observed by Karaoglan 
53.3% synergy. A clinical study in Brazil also showed better clinical 
outcome in 73.8% of patients with this combination therapy with colistin 
and sulbactam86. 
 
              Colistin with Rifampin combination showed 80% (8/10) 
synergy in our study, where as song et al observed 100% synergy with this 
combination they also found positive results in animal mouse model which 
showed 6 day survival rate with this combination87.   
 
Combination of colistin with ciprofloxacin 
 Cagla Bozkurt88 et al observed 45% (9/20isolates) synergy with this 
combination of colistin with ciprofloxacin where as 10% synergy was only 
seen in our study. 
 
 
  
Combination of colistin with imipenem 
                            We observed 77.77% synergy with imipenem when 
combined with Colistin Yoon et al89 found much higher (100%) synergy 
with this combination whereas no synergy in this combination by others 
likes Wareham et al.  
 
                          The drug synergy between colistin and amikacin could not 
be determined as because the MIC of amikacin could not be determined 
(>1024mg/ml) very high resistance. 
 
               One strain developed resistance to colistin after preservation 
and revival indicating the existence of hetro-resistance which has to be 
proved similar observation was made by Li J, Rayner et al90. 
 
                 Difference in synergistic effects of particular combination 
of drugs in different studies where compared to each other may be due to 
clonal difference in Acinetobacter baumannii.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                               7. SUMMARY 
 
 Summary. 
• A total of 163 isolates of Acinetobacter species were characterized by 
both manual phenotypic method and vitek automated identification 
method.  
 
• Acinetobacter baumannii was the most common species(45) followed 
by Acinetobacter species (13), Acinetobacter loffii(3) and 
Acinetobacter haemolyticus(2). 
 
 
• Antibiotic susceptibility testing was done by kirby bauer disk 
diffusion method and vitek automated method. 
 
• Pandrug resistance was seen in <1% of the isolates 
 
 
• Multidrug resistant  and only 73% isolates  
 
•  Carbapanem resistance was seen in 58.02%of the isolates. 
 
 
• Modified Hodge Test was positive in 100% of the isolates 
 • EDTA disk enhanced test was positive in 17% of the isolates 
indicating the metalobetalactamase production.  
 
• Boronic acid test was positive in 2% of the isolates indicating AmpC 
production.   
 
 
•  Molecular characterization of OXA genes were performed in all 
isolate which were positive by MHT  
OXA 51 was seen in 100% of the isolates, conforming the identity of 
the isolates. 
OXA 23 was seen in 93.05% which was also seen in (20.89%) 
isolates that were MBL positive  
OXA 24 and OXA 58 were not seen in any isolate. 
 
• Ten randomly picked isolates of colistin sensitive Acinetobacter 
baumannii were subjected to Drug synergy test by checker board 
method. We observed maximum synergy in colistin with rifampin 
combination(80% and imipenem (77.77%), only 55.55% synergy was 
observed with sulbactam and very poor synergy was observed with 
ciprofloxacin(10%). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                         8. CONCLUSION 
 
 CONCLUSION 
 
                  Acinetobacter baumannii is one of the important nococomial 
pathogen which showed high incidence of carbapenem resistance 
(58.03%). Most common OXA genes found in carbapenem resistant 
Acinetobacter baumannii were OXA 51 and OXA 23.  Metalo-
betalactamese was seen in 18.08% of isolates Best synergy was observed 
with colistin and rifampin (80%) followed by imipenem (77.77%) . 
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